{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:41:20Z","timestamp":1775169680603,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,6,13]]},"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) increase urinary glucose excretion through a reduced renal glucose reabsorption. We plan to perform a systematic review of SGLT-2i for treatment of type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic review with meta-analyses of randomised clinical trials on SGLT-2i versus placebo, other oral glucose lowering drugs or insulin for patients with type 2 diabetes will be performed. The primary end point will be the glycated haemoglobin. Secondary end points will include changes in body weight, body mass index, fasting plasma glucose, plasma cholesterol, kidney and liver blood tests, blood pressure and adverse events. Electronic (the Cochrane Library, MEDLINE, EMBASE and the Science Citation Index) and manual searches will be performed. Meta-analyses will be performed and the results presented as mean differences for continuous outcomes and risk differences for dichotomous outcomes, both with 95% CIs. Subgroup, sensitivity, regression and sequential analyses will be performed to evaluate intertrial heterogeneity, bias and the robustness of results due to cumulative testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study will contribute to the knowledge regarding the beneficial and harmful effects of SGLT-2i in patients with type 2 diabetes. We plan to publish the study irrespective of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study will be disseminated by peer-review publication and conference presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>PROSPERO CRD42014008960<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-005378","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T01:12:20Z","timestamp":1407978740000},"page":"e005378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials"],"prefix":"10.1136","volume":"4","author":[{"given":"Heidi","family":"Storgaard","sequence":"first","affiliation":[{"name":"Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Gastrounit, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"Christensen","sequence":"additional","affiliation":[{"name":"Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark"},{"name":"Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip Krag","family":"Knop","sequence":"additional","affiliation":[{"name":"Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[{"name":"Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,8,13]]},"reference":[{"key":"2025121511180606000_4.8.e005378.1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"2025121511180606000_4.8.e005378.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021778"},{"key":"2025121511180606000_4.8.e005378.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"2025121511180606000_4.8.e005378.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"2025121511180606000_4.8.e005378.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"2025121511180606000_4.8.e005378.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431"},{"key":"2025121511180606000_4.8.e005378.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025121511180606000_4.8.e005378.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"2025121511180606000_4.8.e005378.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"2025121511180606000_4.8.e005378.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"2025121511180606000_4.8.e005378.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"2025121511180606000_4.8.e005378.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"2025121511180606000_4.8.e005378.13","doi-asserted-by":"crossref","unstructured":"Kovacs CS Seshiah V Swallow R . Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:148\u201357.","DOI":"10.1111\/dom.12188"},{"key":"2025121511180606000_4.8.e005378.14","doi-asserted-by":"crossref","unstructured":"Wilding JPH Woo V Rohwedder K . Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124\u201336.","DOI":"10.1111\/dom.12187"},{"key":"2025121511180606000_4.8.e005378.15","unstructured":"EMDAC FDA Backgrounder\u2014UCM378076.pdf. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM378076.pdf ."},{"key":"2025121511180606000_4.8.e005378.16","unstructured":"UCM334550.pdf. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM334550.pdf ."},{"key":"2025121511180606000_4.8.e005378.17","unstructured":"Forxiga, INN-dapagliflozin\u2014WC500136024.pdf. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002322\/WC500136024.pdf ."},{"key":"2025121511180606000_4.8.e005378.18","unstructured":"Invokana_-_CHMP_AR\u2014final\u2014WC500156457.pdf. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002649\/WC500156457.pdf ."},{"key":"2025121511180606000_4.8.e005378.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"2025121511180606000_4.8.e005378.20","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-13-58"},{"key":"2025121511180606000_4.8.e005378.21","doi-asserted-by":"crossref","first-page":"001007","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2,","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"2025121511180606000_4.8.e005378.22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/dom.12239","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis","volume":"16","author":"Goring","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2025121511180606000_4.8.e005378.23","doi-asserted-by":"crossref","unstructured":"Liakos A Karagiannis T Athanasiadou E . Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab Published Online First: 26 April 2014, doi:10.1111\/dom.12307","DOI":"10.1111\/dom.12307"},{"key":"2025121511180606000_4.8.e005378.24","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"2025121511180606000_4.8.e005378.25","unstructured":"Invokana, INN-canagliflozin\u2014WC500156456.pdf. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002649\/WC500156456.pdf ."},{"key":"2025121511180606000_4.8.e005378.26","unstructured":"Jardiance, INN-Empagliflozin\u2014anx_128562_en.pdf. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140522128562\/anx_128562_en.pdf ."},{"key":"2025121511180606000_4.8.e005378.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"2025121511180606000_4.8.e005378.28","unstructured":"ICTRP Search Portal. http:\/\/apps.who.int\/trialsearch\/ ."},{"key":"2025121511180606000_4.8.e005378.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"2025121511180606000_4.8.e005378.30","unstructured":"The Nordic Cochrane Centre. Review Manager (RevMan) . Copenhagen: 2011."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-005378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:18:13Z","timestamp":1765826293000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-005378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,13]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1136\/bmjopen-2014-005378"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-005378","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}